Why the study?
Does prasugrel improve safety compared to clopidogrel in patients undergoing percutaneous coronary intervention?
Does prasugrel improve safety compared to clopidogrel in patients undergoing percutaneous coronary intervention?
In a phase 2 study, prasugrel demonstrated low rates of bleeding comparable to clopidogrel when administered at the time of PCI, supporting further phase 3 evaluation.
Supports comparable bleeding safety for prasugrel versus clopidogrel at PCI; extends phase 2 data warranting phase 3 trials.
In this phase 2 study, which was designed to assess safety when administered at the time of percutaneous coronary intervention, prasugrel and clopidogrel both resulted in low rates of bleeding. The results of this trial serve as a foundation for the large phase 3 clinical trial designed to assess both efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Wiviott et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: